MBX Biosciences, Inc. (NASDAQ:MBX) Receives $51.56 Consensus Target Price from Analysts

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) have received an average rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and ten have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $51.5556.

A number of equities research analysts have recently weighed in on MBX shares. Stifel Nicolaus boosted their price objective on shares of MBX Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Guggenheim lifted their target price on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. The Goldman Sachs Group assumed coverage on shares of MBX Biosciences in a research note on Thursday, December 4th. They issued a “sell” rating and a $18.00 price target for the company. Wall Street Zen upgraded shares of MBX Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, December 21st. Finally, UBS Group reaffirmed a “buy” rating on shares of MBX Biosciences in a research note on Tuesday, February 24th.

MBX Biosciences Stock Down 7.4%

NASDAQ:MBX opened at $30.54 on Friday. The company has a market cap of $1.37 billion, a P/E ratio of -12.78 and a beta of 1.06. The stock has a 50 day moving average price of $35.89. MBX Biosciences has a 1-year low of $4.81 and a 1-year high of $44.89.

Hedge Funds Weigh In On MBX Biosciences

Large investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in MBX Biosciences in the fourth quarter valued at approximately $574,000. Invesco Ltd. increased its stake in shares of MBX Biosciences by 79.9% in the fourth quarter. Invesco Ltd. now owns 21,203 shares of the company’s stock worth $669,000 after buying an additional 9,415 shares during the period. KVP Capital Advisors LP purchased a new position in shares of MBX Biosciences in the fourth quarter worth $3,833,000. Opaleye Management Inc. raised its holdings in MBX Biosciences by 2.8% during the 4th quarter. Opaleye Management Inc. now owns 260,000 shares of the company’s stock valued at $8,200,000 after buying an additional 7,000 shares during the last quarter. Finally, Elmind Capital LP purchased a new stake in MBX Biosciences during the 4th quarter valued at $6,655,000.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.